MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cgh.2017.02.020

Медицинская библиотека · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017

Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.

Crespo Javier, Calleja Jose Luis, Fernández Inmaculada, Sacristan Begoña, Ruiz-Antorán Belén, Ampuero Javier, Hernández-Conde Marta, García-Samaniego Javier, Gea Francisco, Buti Maria, Cabezas Joaquin, Lens Sabela, Morillas Rosa Maria, Salcines Jose Ramon, Pascasio Juan Manuel, Turnes Juan, Sáez-Royuela Federico, Arenas Juan, Rincón Diego, Prieto Martin, Jorquera Francisco, Sanchez Ruano Juan Jose, Navascués Carmen A, Molina Esther, Moya Adolfo Gallego, Moreno-Planas José Maria, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group

СтатьяПеревод пока не подготовлен

Аннотация

Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of second-generation direct-acting antiviral agents (DAAs). More data are needed to help guide treatment decisions. We investigated the effectiveness and safety of DAAs in patients with genotype 4 infection in routine practice. In this cohort study, HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/ritonavir (OMV/PTVr) + ribavirin (RBV) (n=122) or ledipasvir/sofosbuvir (LDV/SOF) ± RBV (n=130) included in a national database were identified and prospectively followed up. Demographic, clinical and virologic data and serious adverse events (SAEs) were analyzed. Differences between treatment groups mean that data cannot be compared directly. Overall sustained virologic response at Week 12 post treatment (SVR12) was 96.2% with OMV/PTVr+RBV and 95.4% with LDV/SOF±RBV. In cirrhotic patients, SVR12 was 91.2% with OMV/PTVr+RBV and 93.2% with LDV/SOF±RBV. There was no significant difference in SVR12 according to degree of fibrosis in either treatment group (P = .243 and P = .244, respectively). On multivariate analysis, baseline albumin <3.5 g/dL (OMV/PTVr) and bilirubin >2 mg/dL (both cohorts) were significantly associated with failure to achieve SVR (P < .05). Rates of SAEs and SAE-associated discontinuation were 5.7% and 2.5%, respectively, in the OMV/PTVr subcohort and 4.6% and 0.8%, respectively, in the LDV/SOF subcohort. DAA-based regimens returned high rates of SVR12, comparable to limited data from clinical trials, in cirrhotic and non-cirrhotic HCV genotype 4 patients managed in a realworld setting. Safety profiles of both regimens were good and comparable to those reported for other HCV genotypes.

Для цитирования: Crespo Javier, Calleja Jose Luis, Fernández Inmaculada, Sacristan Begoña, Ruiz-Antorán Belén, Ampuero Javier, Hernández-Conde Marta, García-Samaniego Javier, Gea Francisco, Buti Maria, Cabezas Joaquin, Lens Sabela, Morillas Rosa Maria, Salcines Jose Ramon, Pascasio Juan Manuel, Turnes Juan, Sáez-Royuela Federico, Arenas Juan, Rincón Diego, Prieto Martin, Jorquera Francisco, Sanchez Ruano Juan Jose, Navascués Carmen A, Molina Esther, Moya Adolfo Gallego, Moreno-Planas José Maria, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017. DOI: 10.1016/j.cgh.2017.02.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.